Investors bet on AI drug discovery despite approval gap
US specialist venture firm Dimension Capital raises $800mn fund to back AI-designed medicines
Dimension Capital, a US specialist venture firm, has successfully raised an $800 million fund. This fund is specifically allocated to support the development of medicines designed using artificial intelligence. The investment signals confidence in AI’s role within the pharmaceutical sector.
- Dimension Capital has raised an $800 million fund.
- The fund will support AI-designed medicines.
- This investment highlights confidence in AI within the pharmaceutical industry.
Continue reading https://www.ft.com/content/d75ca6b2-46f5-4343-a364-21a4440f5197
Write a comment